Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.

Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA, Davidson NE.

Breast Cancer Res Treat. 2010 May;121(1):111-20. doi: 10.1007/s10549-010-0838-7. Epub 2010 Mar 24.

2.

HER2-positive breast cancer: update on Breast Cancer International Research Group trials.

Nabholtz JM, Reese DM, Lindsay MA, Riva A.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S75-9. Review.

PMID:
12435291
3.

Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.

Sparano JA.

Semin Oncol. 2001 Feb;28(1 Suppl 3):20-7. Review.

PMID:
11301371
4.

Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.

Chien KR.

Semin Oncol. 2000 Dec;27(6 Suppl 11):9-14; discussion 92-100. Review.

PMID:
11236034
5.

Breast cancer therapy and cardiovascular risk: focus on trastuzumab.

Sandoo A, Kitas GD, Carmichael AR.

Vasc Health Risk Manag. 2015 Apr 7;11:223-8. doi: 10.2147/VHRM.S69641. eCollection 2015. Review.

Supplemental Content

Support Center